Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $595.5 million.

  • Axsome Therapeutics' Total Liabilities rose 2709.64% to $595.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 2709.64%. This contributed to the annual value of $511.5 million for FY2024, which is 2875.3% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Total Liabilities stood at $595.5 million, which was up 2709.64% from $566.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Total Liabilities registered a high of $595.5 million during Q3 2025, and its lowest value of $73.9 million during Q1 2022.
  • Moreover, its 4-year median value for Total Liabilities was $397.3 million (2023), whereas its average is $367.6 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 27551.93% in 2023, then surged by 2709.64% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Total Liabilities stood at $221.9 million in 2022, then soared by 79.01% to $397.3 million in 2023, then grew by 28.75% to $511.5 million in 2024, then rose by 16.43% to $595.5 million in 2025.
  • Its last three reported values are $595.5 million in Q3 2025, $566.7 million for Q2 2025, and $543.5 million during Q1 2025.